← All indications
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
Drugs by status
Approved for this indication (7)
Phase 4 trials (1)
Phase 3 trials (11)
Phase 2 trials (67)
- decitabine
- azacitidine
- aop2014
- acetylcysteine
- venetoclax
- mirabegron
- busulfan
- canakinumab
- lenalidomide
- prednisone
- selinexor
- tacrolimus
- glasdegib
- imatinib
- naltrexone
- aldesleukin
- idasanutlin
- Imetelstat
- nivolumab
- itacitinib
- pembrolizumab
- lcl-161
- lestaurtinib
- ns-018
- panobinostat
- pat-1251
- pd-l1 peptide vaccine
- pevonedistat
- piperine
- prm-151
- +37 more
Phase 1 trials (27)
Organizations
Organization Involved with Phase 3 Indications (28)
- Celgene
- Roche
- Gilead Sciences
- AOP Orphan Pharmaceuticals AG
- Novartis
- CTI BioPharma
- Constellation Pharmaceuticals
- Sierra Oncology, Inc.
- National Cancer Institute (NCI)
- National Cancer Institute, France
- University of London
- Queen's University, Belfast
- RWTH Aachen University
- University of Southern Denmark
- University of Birmingham
- Mayo Clinic
- Icahn School of Medicine at Mount Sinai
- University of Vienna
- Medical University of Vienna
- Mario Negri Institute
- University of Texas at Houston
- Myeloproliferative Disorders Research Consoritum
- University of Paris
- University of Brescia
- Agenzia Italiana del Farmaco
- Assistance Publique - Hôpitaux de Paris
- MPN Voice
- PharmaEssentia Corp.
Organization Involved with Phase 2 Indications (50)
- S*BIO
- Jazz Pharmaceuticals
- YM Biosciences
- Cephalon
- Bristol-Myers Squibb
- OSI Pharmaceuticals
- Pfizer
- Sanofi
- Baxalta
- Geron Corporation
- Italfarmaco
- Karyopharm Therapeutics Inc
- Promedior, Inc.
- Protagonist Therapeutics
- Imago BioSciences
- National Heart, Lung, and Blood Institute (NHLBI)
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Johns Hopkins University
- McGill University
- Melbourne Health
- PV-Nord
- Stanford University
- Swiss Group for Clinical Cancer Research
- Thomas Jefferson University
- University of Miami
- University of Milan
- University of Oklahoma
- +20 more
Organization Involved with Phase 1 Indications (18)
- AstraZeneca
- Eli Lilly
- Exelixis
- Sponsor GmbH
- TargeGen
- Forbius
- University of Pittsburgh
- AIDS Malignancy Consortium
- Northwestern University
- University of Maryland
- Vanderbilt University
- Institut Gustave Roussy
- City of Hope National Medical Center
- University of Texas, San Antonio
- The Leukemia and Lymphoma Society
- Samus Therapeutics
- The University of Texas, Dallas
- Myeloproliferative Neoplasm Research Consortium (MPN-RC)
Organization Involved with Other Experimental Indications (1)